ARWR

$0.00

(

0.00%

)
Quote details

stock

Arrowhead Pharmaceuticals Inc

NASDAQ | ARWR

52.70

USD

$0.00

(

0.00%

)

At Close (As of Nov 28, 2025)

$7.29B

Market Cap

-

P/E Ratio

-0.01

EPS

$59.15

52 Week High

$9.57

52 Week Low

HEALTHCARE

Sector

ARWR Chart

Recent Chart
Price Action

ARWR Technicals

Tags:

ARWR Earnings

Yearly Income Statement (As of Sep 30, 2025)

Field Value (USD)
Gross Profit -
Total Revenue $829M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income $98M
Selling General And Administrative $124M
Research And Development $607M
Operating Expenses $731M
Investment Income Net -
Net Interest Income -$52M
Interest Income $37M
Interest Expense $89M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax $20M
Income Tax Expense $21M
Interest And Debt Expense -
Net Income From Continuing Operations $30M
Comprehensive Income Net Of Tax -
Ebit -
Ebitda $98M
Net Income -$1.6M

Revenue & Profitability

Earnings Performance

ARWR Financials

yearly Balance Sheet (As of Sep 30, 2025)

Field Value (USD)
Total Assets $1.4B
Total Current Assets $951M
Cash And Cash Equivalents At Carrying Value $89M
Cash And Short Term Investments $89M
Inventory -
Current Net Receivables $6.8M
Total Non Current Assets $435M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $6.9M
Intangible Assets Excluding Goodwill $6.9M
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $693M
Other Current Assets $162M
Other Non Current Assets -
Total Liabilities $686M
Total Current Liabilities $195M
Current Accounts Payable $18M
Deferred Revenue -
Current Debt -
Short Term Debt $7.3M
Total Non Current Liabilities $491M
Capital Lease Obligations $111M
Long Term Debt $215M
Current Long Term Debt $40M
Long Term Debt Noncurrent -
Short Long Term Debt Total $111M
Other Current Liabilities $168M
Other Non Current Liabilities -
Total Shareholder Equity $466M
Treasury Stock -
Retained Earnings -$1.6B
Common Stock $231K
Common Stock Shares Outstanding $134M

yearly Cash Flow (As of Sep 30, 2025)

Field Value (USD)
Operating Cashflow $180M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $24M
Capital Expenditures $23M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$129M
Cashflow From Financing $74M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $30M

yearly Income Statement (As of Sep 30, 2025)

Field Value (USD)
Gross Profit -
Total Revenue $829M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income $98M
Selling General And Administrative $124M
Research And Development $607M
Operating Expenses $731M
Investment Income Net -
Net Interest Income -$52M
Interest Income $37M
Interest Expense $89M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax $20M
Income Tax Expense $21M
Interest And Debt Expense -
Net Income From Continuing Operations $30M
Comprehensive Income Net Of Tax -
Ebit -
Ebitda $98M
Net Income -$1.6M

ARWR News

ARWR Profile

Arrowhead Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Arrowhead Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm headquartered in Pasadena, California, pioneering the use of its proprietary RNA interference (RNAi) technology to develop transformative therapies for challenging diseases, particularly liver disorders and genetic conditions. With a robust pipeline of drug candidates and a commitment to innovative gene silencing and targeted therapeutics, Arrowhead is at the forefront of addressing significant unmet medical needs. The company's strategic partnerships enhance its capabilities, positioning it to advance a range of candidates through clinical trials and potentially reshape treatment paradigms in the biopharmaceutical landscape.

LPTX
+368.57%
$2.05
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
HBI
-1.82%
$6.47
AMZE
+21.21%
$0.48
VINE
+21.21%
$0.48
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
RUBI
-26.17%
$0.15
BMNR
+4.34%
$33.12
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.91%
$7.68
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
INHD
-0.99%
$0.22
ADD
-25.47%
$0.05
CHR
-3.48%
$0.04
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.84%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.73%
$5.50
F
+0.68%
$13.28
BURU
+9.84%
$0.24
GPUS
-9.24%
$0.30
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
SOFI
+4.31%
$29.72
VALE
+0.79%
$12.61
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.35%
$4.62
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.00%
$7.79
AFMD
-34.94%
$0.18
PFE
+0.11%
$25.74
CRCL
+10.03%
$79.93
SMX
+250.80%
$61.04
KWM
+13.63%
$0.75
DNN
0.00%
$2.56
IBRX
+10.79%
$2.36
VEEE
+45.50%
$2.59
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
CAN
+9.78%
$1.01
AAPL
+0.46%
$278.85
NWTN
-9.09%
$0.70
AIIO
-9.09%
$0.70
AG
+12.73%
$15.23
WBD
+0.50%
$24.00
APLD
+8.66%
$27.10
NGD
+6.50%
$8.35
GOOG
-0.05%
$320.12
IREN
-1.32%
$47.81
RIG
+2.55%
$4.41
GRYP
-10.38%
$1.38
BAC
+1.24%
$53.65
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.67%
$17.27
ITUB
+1.82%
$7.80
AGNC
+0.47%
$10.49
CRCA
+19.56%
$4.40
T
+0.77%
$26.02
AMC
+6.52%
$2.45
VHAI
-25.00%
$0.00
NVO
+1.31%
$49.35
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.54%
$3.70
BTE
+1.89%
$3.22
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
HL
+5.32%
$16.82
CRWV
-1.57%
$73.12
LPTX
+368.57%
$2.05
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
HBI
-1.82%
$6.47
AMZE
+21.21%
$0.48
VINE
+21.21%
$0.48
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
RUBI
-26.17%
$0.15
BMNR
+4.34%
$33.12
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.91%
$7.68
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
INHD
-0.99%
$0.22
ADD
-25.47%
$0.05
CHR
-3.48%
$0.04
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.84%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.73%
$5.50
F
+0.68%
$13.28
BURU
+9.84%
$0.24
GPUS
-9.24%
$0.30
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
SOFI
+4.31%
$29.72
VALE
+0.79%
$12.61
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.35%
$4.62
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.00%
$7.79
AFMD
-34.94%
$0.18
PFE
+0.11%
$25.74
CRCL
+10.03%
$79.93
SMX
+250.80%
$61.04
KWM
+13.63%
$0.75
DNN
0.00%
$2.56
IBRX
+10.79%
$2.36
VEEE
+45.50%
$2.59
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
CAN
+9.78%
$1.01
AAPL
+0.46%
$278.85
NWTN
-9.09%
$0.70
AIIO
-9.09%
$0.70
AG
+12.73%
$15.23
WBD
+0.50%
$24.00
APLD
+8.66%
$27.10
NGD
+6.50%
$8.35
GOOG
-0.05%
$320.12
IREN
-1.32%
$47.81
RIG
+2.55%
$4.41
GRYP
-10.38%
$1.38
BAC
+1.24%
$53.65
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.67%
$17.27
ITUB
+1.82%
$7.80
AGNC
+0.47%
$10.49
CRCA
+19.56%
$4.40
T
+0.77%
$26.02
AMC
+6.52%
$2.45
VHAI
-25.00%
$0.00
NVO
+1.31%
$49.35
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.54%
$3.70
BTE
+1.89%
$3.22
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
HL
+5.32%
$16.82
CRWV
-1.57%
$73.12

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.